ReviewCureus2025
Decoding Silent Signals: A Systematic Review of ECG and the Quest for an Early Diagnosis of Cirrhotic Cardiomyopathy.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cirrhotic Cardiomyopathy (CCM) is a well-known cardiac complication with a high incidence of underdiagnosis by healthcare systems in patients with advanced liver disease. While most of the manifestations of cirrhosis stay within the liver function affected, evidence suggests systemic pathology with myocardial dysfunction. Noninvasive ECG markers of potential CCM include QT interval prolongation, QRS hyper-voltage, and T-wave abnormalities. However, the relationship between ECG abnormalities, structural and functional changes in the heart has not been fully described. This systematic review follows Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 reporting guidelines, providing a literature search of ECG changes and evaluation in patients with cirrhosis to establish their diagnostic and predictive value. A structured search of major literature databases showed eight high-quality studies that met the criteria for inclusion in the review. QT prolongation has been associated with the severity of the liver disease, as represented by the clinical scoring system. Changes to the myocardial structure lead to the modification of QRS voltage levels and T-wave configuration, as well as increased arrhythmia risk. Variable sensitivity and specificity were found in diagnosing ventricular function with different echocardiographic parameters, leaving the need for multiple types of diagnostics to provide an accurate evaluation of ventricular function. Identification of ECG abnormalities in different stages of CCM is needed for an early detection system that will result in a higher quality of patient care. Evaluating ECG markers, combined with echocardiography data, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and cardiac troponin biomarkers, leads to improved CCM diagnosis and risk stratification for liver transplant patients. Longitudinal research combined with AI-assisted ECG should be the primary focus in future research for standardization of CCM diagnosis and clinical care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.